Bayer's Deleveraging Momentum Gives Barclays' Bullish Call a Stronger Foundation

Bayer's stock rises 33% YTD as debt outlook improves; Barclays lifts target to €70, citing balance-sheet discipline and Apollo deal.

The investment case for Bayer is quietly shifting from a story about legal overhangs to one about balance-sheet discipline — and the market is starting to pay attention. The stock's 33% year-to-date advance reflects a growing conviction that the Leverkusen-based group has turned a corner, with Tuesday's close at €49.33 capping a 1.3% daily gain.

That same session brought a notable endorsement from Barclays, which lifted its price target from €60 to €70 while reaffirming an "Overweight" stance. The new target sits roughly 42% above the current share price — a bold statement that contrasts with JPMorgan's decision last Thursday to hold its €61 target steady, and UBS's more conservative €62 mark. The divergence among analysts underscores that the Street remains split on just how far Bayer's recovery can run.

What gives the Barclays call its timing? The bank's upgrade lands barely a week after Bayer's crop science investor day, where management laid out five-year targets that included a €1 billion improvement in EBITDA before special items and free operating cash flow exceeding €3 billion by 2029. Cost savings of nearly €400 million have already been banked, according to Reuters — a tangible first installment on that longer-term ambition.

Apollo Deal Accelerates the Balance-Sheet Fix

The debt picture, long the sorest point for Bayer bears, is improving faster than previously guided. Management now expects net financial debt of €29 to €30 billion by year-end 2026, a meaningful reduction from the earlier forecast of €32 to €33 billion. The revision owes much to the July agreement with Apollo Global Management, which is injecting €3 billion in fresh equity for a minority stake in a newly formed entity focused on reversible long-acting contraceptives. Bayer retains majority control and operational oversight, with the transaction slated to close in the third quarter of 2026.

That capital infusion, layered on top of operational improvements, gives the company breathing room to manage its ongoing glyphosate-related litigation without resorting to additional external borrowing. For shareholders who have watched the debt load hang over the stock for years, the structural relief is a meaningful de-risking event.

The first half of 2026 provided the underlying support for the improved outlook. Revenue reached €24.277 billion, a 3.3% increase on an adjusted basis, while EBITDA before special items climbed 6.6% to €6.597 billion. Core earnings per share rose 3.4% to €3.66. Management reaffirmed its full-year guidance across all metrics except the revised debt target, still expecting adjusted EBITDA between €9.6 billion and €10.1 billion and core EPS of €4.30 to €4.90.

Pharma's New Guard Offsets Eylea Pressure

Within the portfolio, the pharma division is demonstrating that it can compensate for its aging stars. Nubeqa and Kerendia together grew 66%, more than offsetting the 27% second-quarter decline at Eylea, which continues to cede ground to biosimilar competition. That mix of emerging strength and mature-market erosion will be a recurring theme in coming quarters.

The deleveraging trajectory also hands a measure of early credibility to Dr. Judith Hartmann, who took over as chief financial officer in early June following Wolfgang Nickl's retirement. Investors will be watching whether she can sustain the momentum, particularly as the glyphosate litigation cycle continues to generate headlines.

The Technical and Fundamental Crossroads

The chart suggests the market is weighing these developments carefully. Bayer shares trade just 1.2% above their 50-day moving average of €48.75, leaving limited cushion against a pullback, while sitting 8.4% below the 52-week high. The rally that characterized the past twelve months has visibly cooled on a weekly and monthly basis. The relative strength index at 56.2 points to neither overbought nor oversold conditions — technically, there is room to run if catalysts materialize.

The product pipeline in crop science provides the fundamental fodder for the bull case. Plenexos™ and the Preceon™ Smart Corn System are already being marketed, with Vyconic™ slated for US and Canadian launches in 2027 and Intacta 5+™ following in Brazil for the 2027/2028 season. Management has pointed to more than 15 new modes of action in research and the scaling of the CropKey platform as sources of optionality beyond the immediate planning horizon. The promised €3.5 billion in additional revenue and cumulative working capital releases of €1.5 billion would, if delivered, go a long way toward closing the valuation gap Barclays has identified.

What Could Derail the Re-Rating

The bear case is equally straightforward. A five-year target horizon leaves ample room for macroeconomic shocks, competitive pressure in agriculture, or regulatory delays. The roughly €400 million in cost savings achieved so far represent only a fraction of the €1 billion goal — if interim milestones disappoint, sentiment could sour quickly. And with the stock hovering barely above its 50-day average, even a modest setback could test that support level.

The near-term catalyst calendar centers on whether the operational milestones outlined at the investor day — particularly the earlier-than-planned working capital improvement — show up in upcoming quarterly reports. Until then, Barclays' €70 target remains an ambitious but unverified wager on the execution capacity of Bayer's agriculture division. The balance-sheet progress, however, gives that bet a firmer foundation than it would have had just a year ago.